Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medtronic (NY: MDT )

84.76 +0.16 (+0.19%)
Official Closing Price Updated: 7:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medtronic

< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Medtronic (MDT) Q1 2025 Earnings Call Transcript
MDT earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Wall Street Eases, Bonds Rises, US Dollar Falls To 8-Month Low: What's Driving Markets Tuesday?
It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices traded in the red at around midday trading in New York. 
Via Benzinga
Nasdaq Moves Lower; Medtronic Posts Upbeat Earnings
Via Benzinga
Key Takeaways From Medtronic Analyst Ratings
Via Benzinga
Looking Into Medtronic's Recent Short Interest
Via Benzinga
Why NYSE:MDT qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of MEDTRONIC PLC (NYSE:MDT). 
Via Chartmill
MDT Stock Earnings: Medtronic Beats EPS, Beats Revenue for Q1 2025
MDT stock results show that Medtronic beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2025. 
Via InvestorPlace
Medical Devices Giant Medtronic Q1 Earnings: Revenue And EPS Beat, Lifts Annual Guidance Marginally On Sustained Growth From New Product Launches
Medtronic beats Q1 2025 earnings and revenue estimates with $7.9 billion in sales, driven by growth in Cardiac, Neuromodulation, and Diabetes segments. The company raises FY25 guidance, citing strong... 
Via Benzinga
Medtronic Posts Modest Beat-And-Raise Report For Fiscal First Quarter
Medtronic stock rose early Tuesday after the medtech company reported slightly better-than-expected results for its fiscal first quarter. 
Via Investor's Business Daily
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks
The gravity-defying climb faces risk, as the index futures trade narrowly mixed in early trading on Tuesday. That said, the recent gains could keep traders wary of a potential pullback. 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Lowe's, Palo Alto Networks And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
5 Dividend Growth Stocks to Buy and Hold Forever
Dividend growth stocks offer investors a powerful combination of income and capital appreciation potential, making them attractive for long-term portfolios. 
Via The Motley Fool
3 Dividend Stocks to Double Up On Right Now
How does a 5.7% dividend yield sound? 
Via The Motley Fool
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
7 Defensive Stocks to Buy as Investors Seek Shelter
With the market primed for more jitters, investors should consider battening down the hatches with these defensive stocks. 
Via InvestorPlace
TJX To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia 
Via MarketBeat
Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
An unexpected diabetes partnership with Medtronic bodes well for Abbott's biggest growth driver. 
Via The Motley Fool
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
Medical Technology Stock Benefits from Rising Acute Care Demand
Medical and surgical products manufacturer Stryker Co. (NYSE: SYK) is a beneficiary of the acute care boom occurring in the healthcare industry. 
Via MarketBeat
Topics Supply Chain
Exposures Supply Chain
Why Intuitive Surgical Stock is Dominating the Medical Sector
Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. However 
Via MarketBeat
2 Dividend Stocks to Buy and Never Sell
These two are rock-solid businesses with strong dividend programs. 
Via The Motley Fool
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily
3 AI-Powered Healthcare Stocks Transforming Medicine
Invest in AI healthcare stocks to benefit significantly from tech that could propel the healthcare market to $148.4 billion by 2029. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 AI-in-Healthcare Stocks to Buy for Outsized Returns
These are the AI healthcare stocks to buy as they represent medical technology investing in research and development for accelerated growth. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Blue-Chip Stocks to Buy for the Second Half of 2024
Despite recent scrutiny, blue-chip stocks offer a chance to capitalize on market lulls and a sector snapback 
Via InvestorPlace
7 Blue-Chip Stocks to Buy on the Dip: July 2024
Buy high-quality at relative bargain prices, if you decide to take advantage of recent weakness with these seven blue-chip stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.